Metoprolol Succinate Cilnidipine Tablet
Description
METROOT-CL
Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg
Cilnidipine IP — 10 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
METROOT-CL is a scientifically balanced antihypertensive combination of Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the advanced dual calcium channel blocking action of Cilnidipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular and renal protection.
Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Cilnidipine is a unique dual L-type and N-type calcium channel blocker that reduces peripheral vascular resistance, suppresses sympathetic overactivity, improves renal hemodynamics, and minimizes reflex tachycardia.
METROOT-CL is particularly beneficial in patients with hypertension associated with tachycardia, diabetes, chronic kidney disease, coronary artery disease, metabolic syndrome, obesity, and patients requiring combination antihypertensive therapy with heart rate control.
Technical Knowledge of Metoprolol Succinate Extended Release and Cilnidipine
Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day.
Cilnidipine blocks both L-type calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals. This dual mechanism reduces arterial vasoconstriction while decreasing sympathetic neurotransmitter release, resulting in sustained blood pressure reduction, improved renal perfusion, reduced glomerular hypertension, and better autonomic control.
The combination of Metoprolol Succinate Extended Release and Cilnidipine provides complementary antihypertensive mechanisms with additional cardiovascular, renal, and endothelial protective benefits.
Mechanism of Action
Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.
Cilnidipine blocks L-type and N-type calcium channels, relaxes vascular smooth muscle, suppresses sympathetic activity, improves renal blood flow, reduces glomerular pressure, and provides sustained antihypertensive action.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular and renal protection
Improves endothelial function
Reduces sympathetic overactivity
Minimizes reflex tachycardia
Suitable for long-term hypertension management under medical supervision
Clinical Applications
METROOT-CL is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with coronary artery disease, metabolic syndrome, obesity-associated hypertension, and long-term cardiovascular risk reduction.
Facts About Metoprolol Succinate Extended Release and Cilnidipine
Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Cilnidipine is an advanced calcium channel blocker with dual L-type and N-type channel blocking properties, providing effective blood pressure control with favorable renal and sympathetic modulation effects. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control.
Key Facts
Beta-blocker and dual calcium channel blocker combination therapy
Metoprolol Succinate Extended Release 25 mg for sustained heart rate control
Cilnidipine 10 mg for vascular and renal protection
Provides sustained 24-hour antihypertensive action
Effective in hypertension with tachycardia and diabetes
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
METROOT-CL is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose METROOT-CL for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 25 mg and Cilnidipine 10 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
METROOT-CL from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Cilnidipine formulation.
